Streetbeat News

CVKD

Cadrenal Therapeutics, Inc. Common Stock

https://www.cadrenal.com

Industry

Biotechnology

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Open

16.50

Mkt cap

17M

Volume

117K

High

18.01

P/E Ratio

-3.39

52-wk high

32.55

Low

15.61

Div yield

N/A

52-wk low

5.40

Cadrenal Therapeutics shares rose following the announcement of raising $5.1 million through its at-the-market facility.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 4:35 pm

Cadrenal Therapeutics has raised $5.1 million through an ATM facility by selling 391,243 shares at an average price of $13.15 per share. The total shares outstanding are now 1,496,771, and the company's cash balance is $7.4 million.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 1:02 pm

Champions Oncology (NASDAQ:CSBR) shares surged over 13% in pre-market trading after reporting better-than-expected Q1 earnings. Other notable pre-market movers include Smart for Life, Protagenic Therapeutics, and NETGEAR, with significant gains, while Ryde Group and Syra Health saw substantial declines.

Portfolio Pulse from Avi Kapoor

September 12, 2024 | 9:46 am

Cadrenal Therapeutics is set to have a Type-B meeting with the FDA in September to discuss the development of tecarfarin for LVAD patients. This meeting is a significant step towards their pivotal trial.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2024 | 1:04 pm

Cadrenal Therapeutics has highlighted a manuscript published in the Journal of Cardiac Failure. The study evaluates the relationship between transthyretin (TTR) management quality and clinical outcomes for patients with left ventricular assist devices (LVAD).

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 1:21 pm

Trading for CVKD has been halted as of 7:50:00 p.m. ET due to pending news. This indicates that significant information regarding the company is expected to be released soon, which could impact its stock price.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 11:50 pm

Cadrenal Therapeutics shares are trading lower after the company reported worse-than-expected Q2 EPS results.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 1:09 pm

Cadrenal Therapeutics (NASDAQ:CVKD) reported a Q2 EPS of $(0.15), missing the analyst consensus estimate of $(0.08) by 87.5%. This represents a 66.67% increase in losses compared to $(0.09) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 8:35 pm

Cadrenal Therapeutics (NASDAQ:CVKD) and Abbott (NYSE:ABT) are collaborating on a pivotal study of tecarfarin, a novel anticoagulant, for patients with recently implanted LVADs. Tecarfarin aims to prevent heart attacks, strokes, and deaths due to blood clots in these patients.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 1:27 pm

HC Wainwright & Co. has reiterated its Buy rating on Cadrenal Therapeutics (NASDAQ:CVKD) and maintained a price target of $3.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 10:46 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.